Axogen director Amy Wendell sells $646k in shares
Amy McBride Wendell, a director at Axogen Inc., sold approximately $646,592 worth of the company's stock on August 11, 2026. The sale involved 13,353 shares, acquired through the exercise of employee stock options, which were fully vested on May 14, 2018. Ms. Wendell sold the shares at a weighted average price of $48.423 per share, executing the transaction in multiple trades with prices ranging from $47.82 to $49.02 per share.
The sale occurred near the stock's 52-week high of $49.93 and follows the stock's remarkable 226% return over the past year. Axogen has a Fair Value of $48.43, suggesting the stock may be overvalued. Ms. Wendell now directly holds 107,976 shares of Axogen common stock. Axogen reported a 23% revenue increase to $69.7 million for its second quarter of 2026, surpassing estimates.
Despite a net loss of $1.5 million, the company's adjusted net income met expectations at $7.3 million. Analysts at H.C. Wainwright and Citizens raised their price targets for Axogen, maintaining Buy and Market Outperform ratings, respectively. This growth and performance have garnered positive attention from financial experts.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
